Money and Computing
Jo Freeman: There’s Plenty To Do at the RNC – If You Have the Right Credentials
by Jo Freeman
Every national nominating convention has plenty of auxiliary events, some authorized, some not. Getting space can be a challenge; getting the word out even more so. But they do it nonetheless. Press were given a RNC 2024 Master Event Calendar, which was updated a few days later. Events began on Sunday and ended on Thursday. The actual convention sessions were just one item on the list. The calendar said if an event was Open or Closed to press, and also whom to contact to register. I’m going to describe some of the events, including a couple I went to, and a couple I was turned away from.
Since my focus is on women, I obviously wanted to go to those events – if I could.
The National Federation of Republican Women is the largest grassroots Republican women's organization in the country with hundreds of clubs. Founded in 1938, its members made the phone calls and knocked on the doors that elected Republican candidates for decades. It’s Tuesday luncheon featured Arkansas Governor Sarah Sanders. The Master Calendar said it was SOLD OUT and they wouldn’t let me in. I was able to get into their lounge at the Fiserv Forum Wednesday evening, where I was repeatedly asked if I was a member, and if not, would I join. “I’m press,” I said. “I can’t join anything partisan.” I then said: “What brings you here?” On hearing that, finding anyone willing to chat with me was like pulling teeth.
Moms for Liberty met in a concert hall that afternoon. I had pre-registered, and I got in. From high in a balcony seat I listened to several people talk about the evils of transgenderism. It’s webpage says WE BELIEVE Power Belongs to the People. Sound Familiar? With a focus is on parental rights, it wants to “STOP WOKE indoctrination.”
Tuesday I went to “The New Mavericks” reception co-hosted by the Black Republican Mayors Association and the Georgia Republican Party. They honored Sen. Tim Scott, four Congressmen and two Georgia delegates – all male. There was only one mayor on stage, from Aurora, IL. The chair of the Georgia Republican Party was the one white man on the stage. At that event, women served; they didn’t speak. The RNC reported that 55 delegates to the 2024 convention are Black, up from 18 in 2016.
I missed the Independent Women’s Forum toast to “Women Who Make Our Country Great” because I went to Convention Fest: The Official Delegate Experience, which was held in the streets outside the Fiserve Forum and Baird Hall as well as some space inside Baird. To get to that one you not only needed a credential of some sort, but a USSS pass (which I have).
Concerned Women for America parked its pink bus across from the Baird Center the week before the RNC. No one was home. When Convention Fest opened on Tuesday afternoon, they set up a pink tent, from which its leaders preached to whomever passed by. It calls itself “the nation’s largest public policy women’s organization” but its focus is evangelical Christian. The slogan on the side of its pink bus captures this emphasis: “She Prays, She Votes.” A prayer precedes each sermon.
US Government Accountability Office (aka GAO): US Postal Service: Customer Complaints Process
GAO: "The US Postal Service's financial viability has been on our High Risk List since 2009. Declining mail volumes and increased costs have made it harder for USPS to cover all its costs. USPS cites quality customer service as important to sustaining its business. We looked at USPS's process for addressing residential customer complaints. In fiscal year 2020, USPS received 10.7 million complaints, with 69% of those related to missing or delayed packages. USPS started using a new software system in 2019 to track complaints and customer service issues. The system collects more detailed data and may help identify the causes of some problems." more »
91.0% Efficacy In Preventing Symtomatic Disease: US Clinical Trial Results Show Novavax Vaccine is Safe and Prevents COVID-19
Results from a Phase 3 clinical trial enrolling 29,960 adult volunteers in the United States and Mexico show that the investigational vaccine known as NVX-CoV2373 demonstrated 90.4% efficacy in preventing symptomatic COVID-19 disease. The candidate showed 100% protection against moderate and severe disease. In people at high risk of developing complications from COVID-19 (people 65 years or older and people under age 65 with certain comorbidities or with likely regular exposure to COVID-19), the vaccine showed 91.0% efficacy in preventing symptomatic COVID-19 disease. more »
Prices are Spiking for Homes, Cars and Gas; Don’t Be Alarmed, Economists Say
Republican political leaders are blaming Democratic President Joe Biden for accelerating inflation. But Jerome Powell, chairman of the US Federal Reserve Board, was appointed by Republican President Donald Trump — and the Fed says inflation will not be a long-term problem. Those numbers suggest that inflationary pressures are modest. Other dynamics, however, are unprecedented, reflecting deeper changes in the economy that may have accelerated with the pandemic. But at UC Berkeley, high-level economists are offering some calming advice: A measure of inflation is inevitable as the US economy comes back online, but it will likely be modest. And it will almost certainly blow over as the economy stabilizes. more »
Kaiser Family Foundation: FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries
"The question of what would happen when a new, expensive prescription drug comes to market for a disease like Alzheimer’s that afflicts millions of people has loomed large in discussions over drug prices in the U.S.— and now we’re about to find out. After a nearly 20-year dry spell in new treatments for Alzheimer’s disease, the Food and Drug Administration (FDA) just approved a new Alzheimer’s medication, Aduhelm (aducanumab), developed by Biogen, with an expected annual price tag of $56,000. While the scientific community debates the evidence of the effectiveness of this new drug, the FDA’s decision raises hope for Alzheimer’s patients and their families, along with serious cost concerns for patients and payers, particularly Medicare." more »